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Abstract
Background:  Skin manifestations of Tuberous Sclerosis Complex (TSC) cause significant
morbidity. The molecular mechanism underlying TSC is understood and there is evidence that
systemic treatment with rapamycin or other mTOR inhibitors may be a useful approach to targeted
therapy for the kidney and brain manifestations. Here we investigate topical rapamycin in a mouse
model for TSC-related tumors.
Methods: 0.4% and 0.8% rapamycin ointments were applied to nude mice bearing subcutaneous,
TSC-related tumors. Topical treatments were compared with injected rapamycin and topical
vehicle. Rapamycin levels in blood and tumors were measured to assess systemic drug levels in all
cohorts.
Results: Treatment with topical rapamycin improved survival and reduced tumor growth. Topical
rapamycin treatment resulted in systemic drug levels within the known therapeutic range and was
not as effective as injected rapamycin.
Conclusion: Topical rapamycin inhibits TSC-related tumor growth. These findings could lead to
a novel treatment approach for facial angiofibromas and other TSC skin lesions.
Background
Tuberous sclerosis complex (TSC) is an autosomal domi-
nant, multi-system tumor disorder characterized by
hamartomatous tumors affecting the brain, kidneys,
lungs, heart and skin. Clinical manifestations of TSC were
recently reviewed [1,2] and major criteria include kidney
angiomyolipomas (AMLs), cardiac rhabdomyomas, facial
angiofibromas, ungual or periungual fibromas, shagreeen
patch, hypomelanotic macule, retinal hamartomas, sub-
ependymal nodules, subependymal giant cell astrocyto-
mas (SEGAs), cortical tubers and
lymphangioleiomyomatosis (LAM). Although TSC-asso-
ciated tumors are benign, TSC patients can have a number
of medical problems including epilepsy, cognitive impair-
ment, behavior problems, brain lesions (tubers and/or
subependymal nodules), skin tumors (facial angiofibro-
mas), cardiac tumors (rhabdomyomas), kidney tumors
(AMLs), kidney cysts, renal cell cancer, and pulmonary
abnormalities including LAM [3-5]. The skin manifesta-
tions of TSC often lead to the diagnosis. Although there
are a variety of skin manifestations, the facial angiofibro-
mas in particular cause significant morbidity for patients
because they occur on the face and current treatment
options are limited [6,7].
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There are two disease genes: TSC1 on 9q34 and TSC2 on
16p13 [8,9]. Their gene products, hamartin and tuberin
respectively, form a tumor suppressor complex [10,11]
that controls a key regulatory kinase, mammalian Target
of Rapamycin (mTOR). When mutations occur in either
gene, the hamartin-tuberin complex does not function
properly and the mTOR pathway is constitutively acti-
vated which leads to dysregulated protein translation, cell
growth and proliferation [12,13]. While a mutation in
either gene has been shown to result in disease [14], TSC2
mutations are 5–6 times more common than TSC1 muta-
tions and have been linked with a more severe phenotype
[3,15,16]. As cells that lack normal tuberin or hamartin
cannot down-regulate the mTOR signaling pathway, there
is significant interest in investigating the utility of mTOR
inhibitors, such as rapamycin and its analogs, to treat
TSC-related tumors. Rapamycin (also known as sirolimus,
Rapamune) is an mTOR kinase inhibitor that is FDA
approved for immunosuppression following kidney
transplantation. There are several rapamycin analogs
(CCI-779, RAD001, and AP23575) that are under investi-
gation as anti-tumor agents [17], and CCI-779 (also
known as Temsirolimus) was recently approved for the
treatment of poor risk metastatic renal cell carcinoma
[18].
The beneficial effects of mTOR inhibitors have been
shown in preclinical studies of TSC rodent models, where
reductions were seen in kidney, subcutaneous and pitui-
tary tumors [19-22]. Furthermore, several case reports
demonstrate regression in kidney AMLs and SEGAs after
rapamycin treatment [23-25] and several mTOR inhibitor
trials for TSC and/or LAM are currently underway.
Skin lesions that occur in TSC include facial angiofibro-
mas, hypomelanotic macules, shagreen patch, and
ungual/periungual fibromas. Facial angiofibromas are red
papules distributed across the face that begin to appear in
early childhood and occur in 60–79% of patients.
Hypomelanotic macules are polygonal white spots that
occur in 89–97% of patients. The shagreen patch is an ele-
vated patch or plaque on the lower back with a surface
resembling an orange peel; these lesions can increase in
size with age and occur in 39–51% of patients. Ungual/
periungual fibromas are growths that originate from
below the proximal nail fold, tend to develop in older
children or adults, and occur in 15–36% of patients
[3,15,16].
While TSC skin lesions are usually not life threatening, the
facial angiofibromas that occur in this population are
prevalent and often disfiguring, resulting in a need for
improving treatment options. The current treatment
options for facial angiofibromas include cryosurgery, der-
mabrasion, surgical excision, and laser therapy. However,
effectiveness varies, complications can occur, recurrence is
common, and repeated treatments are frequently neces-
sary [2,26,27]. Here we investigate the utility of topical
rapamycin as a novel therapeutic strategy for TSC skin dis-
ease by evaluating its efficacy on TSC-related tumors in a
preclinical model.
Methods
Induction of Subcutaneous Tumors in Nude Mice and 
Treatment with Topical Rapamycin
Nude mice (strain CD-1nuBR, up to 6 weeks old) were
obtained from Charles River Laboratories (Wilmington,
Massachusetts). 64 mice were injected with 2.5 million
NTC/T2null (Tsc2-/-, Trp53-/-) cells on their dorsal flanks
as described previously [20]. Cages of 4–8 mice were ran-
domly assigned to treatment groups before tumors
appeared. As soon as tumors were visible, they were meas-
ured five days per week (Monday through Friday) using
calipers. Tumor volumes were then calculated using the
formula: length × width × width × 0.5 [28]. Treatment was
started when tumors reached approximately 200 mm3.
There were a total of five treatment groups: 0.8% (0.16
mg) direct topical rapamycin (n = 13), 0.8% (0.16 mg)
indirect topical rapamycin (n = 12), 0.4% (0.08 mg) direct
topical rapamycin (n = 15), direct topical vehicle control
(n = 12), and 0.16 mg intraperitoneal (IP) rapamycin (n
= 8). The direct topical treatments were applied to the skin
directly over the tumor surface. The indirect topical treat-
ment was applied to skin on the upper back, away from
the tumor. All mice were treated three days a week, Mon-
day, Wednesday and Friday. Each treatment group was
divided in half with one half assigned for euthanization at
24 hours after the final treatment and the other half at 48
hours after the final treatment. Once tumors grew to 3000
mm3, the mice were euthanized at their assigned time
point. Mice were weighed on day one of their treatment
and at necropsy; no notable changes were seen in any
cohorts.
Four mice were excluded from the analysis. Three of these
mice (two assigned to 0.8% direct topical rapamycin and
one assigned to 0.4% direct topical rapamycin) did not
grow large enough tumors to reach the start volume of
200 mm3. One mouse (assigned to 0.8% direct topical
rapamycin) was sacrificed early, when tumor volume was
approximately 1100 mm3, due to significant weight loss
from dehydration which did not appear to be treatment
related. All procedures were approved by our animal insti-
tutional review board (Children's Hospital, Boston, MA)
and were compliant with federal, local, and institutional
guidelines on the care of experimental animals.
To prepare topical ointment, rapamycin powder was
obtained from LC Laboratories (Woburn, Massachusetts)
and two stocks, 40 mg/ml and 20 mg/ml, were made inBMC Dermatology 2008, 8:1 http://www.biomedcentral.com/1471-5945/8/1
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ethanol and stored at -20°C. Single doses of rapamycin
ointment for topical treatments were made by mixing 50
mg petroleum jelly with 10 μl of the corresponding stock
in eppendorf tubes. A 0.8% ointment was made with the
40 mg/ml stock and a 0.4% ointment was made with the
20 mg/ml stock. The ointment was applied using cotton
swabs immediately following mixing. Because we deter-
mined that 60% of each dose adhered to the swab or the
eppendorf tube, the milligram dose of rapamycin actually
applied was 0.16 mg (for the 0.8% ointment) and 0.08
mg (for the 0.4% ointment). For comparison, we also pre-
pared rapamycin for IP injection. This was done by dilut-
ing the 20 mg/ml stock to a final concentration of 0.8 mg/
ml in vehicle (5% PEG, 5% Tween-80) and using it within
24 hours. Animals treated with IP rapamcyin were
injected with 0.2 ml for a rapamycin dose of 0.16 mg.
Whole blood and tumor rapamycin levels
Whole blood and tumor rapamcyin levels were measured
from all animals in the treatment study described above.
Blood and tumors were harvested at 24 or 48 hours after
the final treatment. Tumor samples were prepared by
homogenizing 200 mg of tumor tissue in 1 ml of sterile
saline. Whole blood was obtained by cardiac puncture,
dispensed into an EDTA-containing blood tube, and
diluted with an equal volume of sterile saline to ensure
sufficient volume for rapamycin level analysis. All meas-
ured rapamycin levels were then corrected according to
sample dilution. Rapamycin levels were measured by the
Clinical Laboratory at Children's Hospital Boston (Bos-
ton, Massachusetts). The range of detection is 0.5 to 100
ng/ml.
To further investigate systemic rapamycin levels after top-
ical rapamycin treatment, additional whole blood drug
levels were obtained in control nude mice without tumors
after single or multiple doses of rapamycin treatment. To
demonstrate that significant ingestion of rapamycin oint-
ment during grooming did not occur, Elizabethan collars
(Braintree Scientific, Inc., Braintree, Massachusetts) or
bandages (Tegaderm™ 6 cm × 7 cm transparent dressings,
3 M, St. Paul, Minnesota) were used in some groups of
control animals (see Results). Elizabethan collars were
placed on mice receiving rapamycin prior to drug admin-
istration and remained on for one hour. During this time,
the mice were observed to ensure that visible absorption
of rapamycin ointment had occurred. The bandages were
applied to mice following treatment administration
directly over the target area and remained intact for several
hours in all mice (50% of bandages were intact after 24
hours and none were intact after 48 hours).
Statistical Analyses
GraphPad Prism software (version 4.01) was used for all
data analysis, with a p value ≤ 0.05 indicating statistical
significance. All calculations were completed from raw
data by two authors (AR and NL). A t test was used to test
all quantitative data and the Mantel-Cox logrank analysis
was used for survival data.
Results
Topical Rapamycin Reduces Tumor Growth and Improves 
Survival in Nude Mice Bearing Tsc2-/- Tumors
To determine whether topical rapamycin treatment is a
useful therapeutic approach for TSC skin disease, we
investigated the efficacy of topical rapamycin using a nude
mouse model for TSC-related tumors. TSC is known to be
a tumor suppressor gene disorder [29,30] so the mouse
model for Tsc2-/- tumors used here is a useful generic
model for TSC related tumors. It is known that the Tsc2-/-
tumors in this mouse model have constitutively activated
mTOR kinase [20], and a similar defect in mTOR signaling
is observed in brain and kidney tumors associated with
TSC [31,32]. It is likely that activated mTOR is also
present in some TSC skin lesions because loss of heterozy-
gosity for TSC2 has been demonstrated in a facial angiofi-
broma [33] and tuberin and/or hamartin are absent in
many facial angiofibromas from individuals with TSC
[34].
A cohort of 64 nude mice was injected with NTC/T2null
cells. This cohort was divided into 5 treatment groups:
0.8% direct, 0.8% indirect (shoulder), 0.4% direct, 0.16
mg IP, and topical vehicle control. Doses were based on
pilot studies, Ormerod et al. 2005, and drug level studies
[35]. Animals began treatment when their tumor volume
reached ~200 mm3 and were euthanized at a tumor vol-
ume of ~3000 mm3. Four animals were excluded from
analyses as previously described in the methods. Average
tumor growth is shown for each treatment group in Figure
1A. The data points shown represent days when greater
than or equal to half of the group was treated and had
tumors measured. On day 29, the average tumor volumes
for the 0.4% direct (1568 ± 155 mm3), 0.8% direct (1212
± 118 mm3), and 0.8% indirect (1136 ± 101 mm3) were
all significantly lower than the vehicle-treated cohort
(2736 ± 321 mm3) (Table 1). Improved survival was also
seen in all treated cohorts when compared to the vehicle-
treated cohort (Table 1, Figure 1B). Although administer-
ing the identical rapamycin dose by IP injection is more
effective, this study demonstrates that rapamycin applied
topically does impede TSC tumor growth when compared
to the vehicle.
Comparison of Direct and Indirect Treatment
To test whether topical rapamycin applied to skin directly
over the subcutaneous tumor was more effective than a
topical dose applied several centimeters away from the
tumor surface, the two 0.8% groups were compared.
When evaluating survival between these groups, the dif-BMC Dermatology 2008, 8:1 http://www.biomedcentral.com/1471-5945/8/1
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ference is significant and to our surprise indicated that the
indirect topical treatment was more effective than the
direct treatment (Table 1). On day 45, the difference in
average tumor volumes for the two groups did not meet
our criteria for statistical significance (direct topical
rapamycin 1568 ± 155 mm3, indirect topical rapamycin
1212 ± 118 mm3), but the p value was 0.06.
Rapamycin Drug Level Measurements show Systemic 
Levels are Achieved through Topical Absorption
Rapamycin levels were measured in whole blood (Figure
2, Table 2) and tumors (Figure 3, Table 3) from a subset
of the cohort described above. For whole blood levels,
rapamycin level measurements were taken 24 and 48
hours after the last dose of drug (Figure 2A and 2C). As
demonstrated, levels in the 0.8% topical groups (direct
and indirect) are comparable to levels in corresponding
non-tumor bearing animals (Figure 2B and 2D). This is
true for the 0.4% dose as well. When a 0.16 mg dose is
given by injection, the 24 hour levels in whole blood are
~5 times higher than when administered topically.
Rapamycin levels in tumors are shown in Figure 3 and
Table 3. Both 24 hour and 48 hour levels are shown for all
treatment groups. Both 0.8% direct and indirect topical
doses resulted in similar levels and were ~2–4 times
higher than the 0.4% direct topical dose. Although the
direct application gave a higher average tumor drug level
at 24 hours, this difference was not statistically significant
and was inconsistent with the better survival observed
with indirect treatment. We are unable to explain this
inconsistency and conclude that overall, the two methods
gave very similar results. This data demonstrates that ther-
apeutic systemic levels of rapamycin were achieved after
topical administration in these animals.
In order to verify that the topical rapamycin dose used in
these experiments is relevant to the effective dose
approved for use in humans, we measured whole blood
rapamycin levels in non-tumor bearing animals after sin-
gle and multiple doses. The rapamycin level in whole
blood 24 hours after a single 0.8% dose of topical rapamy-
cin was 13.0 ± 2.5 ng/ml. After a single 0.4% dose the
rapamycin level was 5.9 ± 0.5 ng/ml. These 24 hour levels
are within the typical therapeutic range for rapamycin
when used for immunosuppression after organ transplan-
Table 1: Survival and Tumor Growth Analysis
0.4% Direct Topical 
Rapamycin
0.8% Indirect Topical 
Rapamycin
0.8% Direct Topical 
Rapamycin
0.16 mg Injected (IP) 
Rapamycin
Direct Topical 
Vehicle
Median Survival (days) 41 54 46 74.5 29.5
Logrank Analysis* p = 0.0003 p =< 0.0001 p =< 0.0001 p =< 0.0001 N/A
Logrank Analysis** p = 0.62 p = 0.0003 N/A p =< 0.0001 N/A
Ave. Tumor Vol. (mm3)
Day 29 1568 ± 155 1136 ± 101 1212 ± 118 440 ± 65 2736 ± 321
T test* p = 0.0014 p =< 0.0001 p =< 0.0001 p =< 0.0001 N/A
T test** p = 0.08 p = 0.63 N/A p = 0.0001 N/A
Day 45 N/A 2235 ± 246 2869 ± 188 944 ± 166 N/A
T test** N/A p = 0.06 N/A p =< 0.0001 N/A
Number of Mice 15 12 13 8 12
*Compared to vehicle.
**Compared to 0.8% direct topical rapamycin
Topical rapamycin treatment impedes tumor growth and  improves survival Figure 1
Topical rapamycin treatment impedes tumor growth and 
improves survival. Average tumor growth (A) and survival 
curves (B) for indicated treatment groups.
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tation (3–15 ng/ml). 48 hour levels were also measured
and show that in animals treated with a single 0.4% dose,
rapamycin levels dropped below therapeutic range (1.7 ±
0.9 ng/ml) while those treated with a single 0.8% dose did
not (4.1 ± 2.3 ng/ml). In addition, we measured rapamy-
cin levels using two barrier methods to ensure that inges-
tion due to grooming was not a contributing factor
(Figure 2B and 2D, Table 2). Several animals were fitted
with Elizabethan collars for one hour after topical
rapamycin was applied so they were unable to groom the
area with ointment. There were 6 animals in the Eliza-
bethan collar group and all were treated with three 0.8%
doses of topical rapamycin (on days 1, 4 and 6) with the
average rapamycin level in whole blood at 24 hours after
the last dose being 21.7 ± 3.7 ng/ml. As this level was
slightly higher but not significantly different than in ani-
mals with no barriers to prevent grooming, it provides evi-
dence that grooming does not seem to increase whole
blood levels of rapamycin after topical treatment. We also
used bandages (Tegaderm™ 6 cm × 7 cm transparent dress-
ings) as a grooming prevention strategy and were sur-
prised to find significantly lower rapamycin levels in this
group at 24 hours but not 48 hours. This suggests that the
bandages may significantly alter absorption kinetics of
rapamycin so that the dose penetrating the skin is lower at
24 hours. Our finding that the 48 hour level in the band-
age group is not significantly different from the 48 hour
levels in the no barrier topical group suggests that the
Rapamycin whole blood levels after treatment with topical and IP rapamycin Figure 2
Rapamycin whole blood levels after treatment with topical and IP rapamycin. A) Whole blood rapamycin levels from tumor 
bearing animals from indicated treatment groups. Rapamycin levels were measured 24 hours after the final dose of rapamycin. 
B) Whole blood rapamycin levels were measured in cohorts of control mice with no tumors. As indicated, levels were meas-
ured 24 hours after either one or three doses of topical rapamycin. In some groups, Elizabethan collars or bandages were used 
to prevent ingestion of rapamycin ointment. All animals had rapamycin levels >3 ng/ml. The slightly higher levels in the Eliza-
bethan collar group suggests that ingestion is not a major issue. The lower levels in the bandage groups suggests that the band-
age polymer can affect drug absorption. C) Whole blood rapamycin levels were also measured 48 hours after the final dose in 
tumor bearing animals. D) In three of the control, non-tumor bearing groups, rapamycin levels were measured at 48 hours fol-
lowing their final treatment to compare to tumor bearing animals.
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bandage may provide a means for sustained release of top-
ical rapamycin, but this will require further studies. In
summary, these data demonstrate that a relevant dose of
topical rapamycin was used, it is unlikely that drug inges-
tion during grooming increases drug levels, and Tega-
derm™ bandages may affect rapamycin ointment
absorption as applied for these studies.
Discussion
We have shown through survival and tumor growth anal-
yses that rapamycin administered topically is an effective
treatment for reducing TSC tumor growth in a preclinical
model. The efficacy of topical rapamycin has not previ-
ously been studied in TSC preclinical models, but prior
studies have shown that 0.4–3.6% topical rapamycin was
effective in a mouse model for irritant dermatitis [36] and
1% topical rapamycin was effective in a mouse model of
allergic dermatitis [37]. In a randomized, double-blind
clinical trial, 8% topical rapamycin was effective for the
treatment of psoriasis and there was evidence of skin pen-
etration without measurable rapamycin in blood [35].
There is also evidence of a reduced incidence of skin and
non-skin cancers when rapamycin is used for immuno-
suppression instead of other agents following kidney
transplantation [38,39]. Furthermore, systemic rapamy-
cin treatment is effective in the treatment of Kaposi's Sar-
coma [40,41]and in preclinical studies of melanoma [42].
Finally, a study showing decreased expression of the TSC2
gene product, tuberin, in sporadic squamous and basal
cell carcinomas suggests that mTOR inhibitors may be
useful in treating these common skin cancers as well [43].
In our studies of topical rapamycin for TSC tumors, we
found that there was no advantage to applying topical
rapamycin directly to the tumor surface compared with
indirect topical application. In fact, the indirect treatment
was slightly more effective despite similar drug levels in
tumors and whole blood from these cohorts. We also note
Rapamycin levels in tumor samples after treatment with topical or IP rapamycin Figure 3
Rapamycin levels in tumor samples after treatment with topical or IP rapamycin. Rapamycin levels in tumor homogenates from 
indicated treatment groups were measured 24 hours (A, C) and 48 hours (B, D) after the final dose of rapamycin. Panels C and 
D are enlarged versions of the boxed-in data in panels A and B respectively.
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that a limitation of this study is that mice have a signifi-
cantly higher ratio of surface area:volume compared with
humans so both the indirect and direct topical treatments
resulted in 24 hour whole blood and tumor rapamycin
levels within the known therapeutic range for effective
immunosuppression in humans. It is therefore likely that
the effect of topical rapamycin in these experiments was
due to systemic rapamycin exposure. Despite this limita-
tion, this study demonstrates that 0.4–0.8% rapamycin
applied topically does penetrate the skin in this preclinical
model.
Conclusion
In summary, we have shown that topical administration
of rapamycin is an effective treatment for TSC-related
tumors in a mouse model. Our data demonstrates that
transdermal delivery of rapamycin is feasible and topical
rapamycin should be further investigated as a novel treat-
ment approach for TSC skin disease such as facial angiofi-
bromas. Furthermore, the utility of topical rapamycin
should be further investigated for other skin disorders
such as psoriasis, Kaposi's Sarcoma, basal cell carcinoma,
and squamous cell carcinoma.
List of Abbreviations
TSC – Tuberous Sclerosis Complex; mTOR – Mammalian
target of rapamycin; ng – nanogram; mg – milligram; ml
– milliliter; mm – millimeter; cm – centimeter; PEG – Pol-
yethylene glycol; AML – Angiomyolipoma; SEGA – Sub-
ependymal giant cell astrocytoma; LAM –
Lymphangioleiomyomatosis; IP – intraperitoneal
Table 3: Tumor Rapamycin Levels
24 hours 48 hours
Treatment Groups Rapamycin Level 
(ng/ml)
p value* Number of 
Mice
Rapamycin Level 
(ng/ml)
p value** Number of 
Mice
Treatment Trial (Tumor bearing)
0.4% Direct Topical Rapamycin 13.8 ± 0.7 0.12 3 14.2 ± 1.8 0.33 3
0.8% Indirect Topical 
Rapamycin
34.2 ± 9.6 0.37 3 25.8 ± 7.8 0.65 3
0.8% Direct Topical Rapamycin 59.6 ± 23.5 N/A 3 21.0 ± 5.9 N/A 3
0.16 mg Rapamycin IP 421.8 ± 119.4 0.03 2 323.7 ± 98.1 0.03 2
* Compared to 0.8% direct treatment 24 hr tumor level.
** Compared to 0.8% direct treatment 48 hr tumor leve
Table 2: Whole Blood Rapamycin Levels
24 hours 48 hours
Treatment Groups Rapamycin Level (ng/ml) p value* Number of Mice Rapamycin Level (ng/ml) p value** Number of Mice
Treatment Trial (Tumor bearing)
0.4% Direct Topical 
Rapamycin
6.3 ± 0.6 0.02 3 2.3 ± 0.4 0.04 3
0.8% Indirect Topical 
Rapamycin
11.9 ± 3.2 0.92 3 5.3 ± 0.8 0.25 3
0.8% Direct Topical 
Rapamycin
12.3 ± 1.5 N/A 3 4.1 ± 0.5 N/A 3
0.16 mg Rapamycin IP 55.9 ± 2.7 0.0005 2 17.4 ± 2.2 0.005 2
Non-Tumor bearing
0.4% Topical Rapamycin (1 
dose)
5.9 ± 0.5 0.01 3 1.7 ± 0.9 0.07 3
0.8% Topical Rapamycin (1 
dose)
13.0 ± 2.5 0.81 3 4.1 ± 2.3 0.98 3
0.8% Topical Rapamycin + 
Bandage (1 dose)
3.4 ± 0.6 <0.0001 8 2.6 ± 0.7 0.28 8
0.8% Topical Rapamycin + 
Collar (3 doses)
21.7 ± 3.7 0.13 6 Not done N/A Not done
* Compared to 0.8% direct treatment (tumor bearing) 24 hr blood level.
** Compared to 0.8% direct treatment (tumor bearing) 48 hr blood levelBMC Dermatology 2008, 8:1 http://www.biomedcentral.com/1471-5945/8/1
Page 8 of 9
(page number not for citation purposes)
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
SD provided funding, critical guidance for the experi-
ments, and was responsible for supervising the writing
and editing of the manuscript. AR designed most of the
experiments, collected most of the data, performed all sta-
tistical analysis, and wrote the first draft of the manu-
script. NL assisted with experimental design, data
collection, and independent verification of statistical
analyses. LL assisted in planning the experiments, critical
evaluation of data, and editing the manuscript. All
authors have read and approved the final manuscript.
Acknowledgements
This work was funded by a Harvard Skin Disease Center Pilot Project 
Grant and NIH (NIDDK) Grant number R01 DK066366. We thank Michael 
Messina for technical assistance.
References
1. Crino PB, Nathanson KL, Henske EP: The tuberous sclerosis
complex.  N Engl J Med 2006, 355:1345-1356.
2. Schwartz RA, Fernandez G, Kotulska K, Jozwiak S: Tuberous scle-
rosis complex: advances in diagnosis, genetics, and manage-
ment.  J Am Acad Dermatol 2007, 57:189-202.
3. Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, Choy
YS, Reeve MP, Thiele E, Egelhoff JC, Kasprzyk-Obara J, Domanska-
Pakiela D, Kwiatkowski DJ: Mutational Analysis in a Cohort of
224 Tuberous Sclerosis Patients Indicates Increased Severity
of TSC2, Compared with TSC1, Disease in Multiple Organs.
Am J Hum Genet 2001, 68:64-80.
4. Franz DN, Brody A, Meyer C, Leonard J, Chuck G, Dabora S, Sethura-
man G, Colby TV, Kwiatkowski DJ, McCormack FX: Mutational
and radiographic analysis of pulmonary disease consistent
with lymphangioleiomyomatosis and micronodular pneu-
mocyte hyperplasia in women with tuberous sclerosis.  Am J
Respir Crit Care Med 2001, 164:661-668.
5. Gomez MR, Sampson JR, Whittemore VH: The tuberous sclerosis
complex.  Third Ed. edition. Oxford, England, Oxford University
Press; 1999. 
6. Kane Y: The "bumps" on my face.  J Am Acad Dermatol 2004,
51:S11-2.
7. Darling TN: Hamartomas and tubers from defects in hamar-
tin-tuberin.  J Am Acad Dermatol 2004, 51:S9-11.
8. European Chromosome 16 Tuberous Sclerosis Consortium: Identi-
fication and characterization of the tuberous sclerosis gene
on chromosome 16.  Cell 1993, 75:1305-1315.
9. van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B,
Verhoef S, Lindhout D, van den Ouweland A, Halley D, Young J, Bur-
ley M, Jeremiah S, Woodward K, Nahmias J, Fox M, Ekong R, Osborne
J, Wolfe J, Povey S, Snell RG, Cheadle JP, Jones AC, Tachataki M,
Ravine D, Kwiatkowski DJ: Identification of the tuberous sclero-
sis gene TSC1 on chromosome 9q34.  Science 1997,
277:805-808.
10. Potter CJ, Huang H, Xu T: Drosophila Tsc1 functions with Tsc2
to antagonize insulin signaling in regulating cell growth, cell
proliferation, and organ size.  Cell 2001, 105:357-368.
11. Gao X, Zhang Y, Arrazola P, Hino O, Kobayashi T, Yeung RS, Ru B,
Pan D: Tsc tumour suppressor proteins antagonize amino-
acid#150;TOR signalling.  Nat Cell Biol 2002, 4:699-704.
12. Findlay GM, Harrington LS, Lamb RF: TSC1-2 tumour suppressor
and regulation of mTOR signalling: linking cell growth and
proliferation?  Curr Opin Genet Dev 2005, 15:69-76.
13. Inoki K, Corradetti MN, Guan KL: Dysregulation of the TSC-
mTOR pathway in human disease.  Nat Genet 2005, 37:19-24.
14. Cheadle JP, Reeve MP, Sampson JR, Kwiatkowski DJ: Molecular
genetic advances in tuberous sclerosis.  Hum Genet 2000,
107:97-114.
15. Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-
Kievit A, Zonnenberg B, Verhoef S, Halley D, van den Ouweland A:
Mutational analysis of the TSC1 and TSC2 genes in a diag-
nostic setting: genotype--phenotype correlations and com-
parison of diagnostic DNA techniques in Tuberous Sclerosis
Complex.  Eur J Hum Genet 2005, 13:731-741.
16. Au KS, Williams AT, Roach ES, Batchelor L, Sparagana SP, Delgado
MR, Wheless JW, Baumgartner JE, Roa BB, Wilson CM, Smith-Knup-
pel TK, Cheung MY, Whittemore VH, King TM, Northrup H: Geno-
type/phenotype correlation in 325 individuals referred for a
diagnosis of tuberous sclerosis complex in the United States.
Genet Med 2007, 9:88-100.
17. Smolewski P: Recent developments in targeting the mamma-
lian target of rapamycin (mTOR) kinase pathway.  Anticancer
Drugs 2006, 17:487-494.
18. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Star-
oslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy
V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten
S, Moore L, Motzer RJ: Temsirolimus, interferon alfa, or both
for advanced renal-cell carcinoma.  N Engl J Med 2007,
356:2271-2281.
19. Lee L, Sudentas P, Dabora SL: Combination of a rapamycin ana-
log (CCI-779) and interferon-gamma is more effective than
single agents in treating a mouse model of tuberous sclerosis
complex.  Genes Chromosomes Cancer 2006, 45:933-944.
20. Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V, Sun
Y, Schmidt K, Albert MS, El-Hashemite N, Lader AS, Onda H, Zhang
H, Kwiatkowski DJ, Dabora SL: Efficacy of a rapamycin analog
(CCI-779) and IFN-gamma in tuberous sclerosis mouse
models.  Genes Chromosomes Cancer 2005, 42:213-227.
21. Kenerson H, Dundon TA, Yeung RS: Effects of rapamycin in the
Eker rat model of tuberous sclerosis complex.  Pediatr Res
2005, 57:67-75.
22. Kenerson HL, Aicher LD, True LD, Yeung RS: Activated Mamma-
lian target of rapamycin pathway in the pathogenesis of
tuberous sclerosis complex renal tumors.  Cancer Res 2002,
62:5645-5650.
23. Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G,
Dinopoulos A, Thomas G, Crone KR: Rapamycin causes regres-
sion of astrocytomas in tuberous sclerosis complex.  Ann Neu-
rol 2006, 59:490-498.
24. Herry I, Neukirch C, Debray MP, Mignon F, Crestani B: Dramatic
effect of sirolimus on renal angiomyolipomas in a patient
with tuberous sclerosis complex.  Eur J Intern Med 2007,
18:76-77.
25. Wienecke R, Fackler I, Linsenmaier U, Mayer K, Licht T, Kretzler M:
Antitumoral activity of rapamycin in renal angiomyolipoma
associated with tuberous sclerosis complex.  Am J Kidney Dis
2006, 48:e27-9.
26. Bittencourt RC, Huilgol SC, Seed PT, Calonje E, Markey AC, Barlow
RJ: Treatment of angiofibromas with a scanning carbon diox-
ide laser: a clinicopathologic study with long-term follow-up.
J Am Acad Dermatol 2001, 45:731-735.
27. Papadavid E, Markey A, Bellaney G, Walker NP: Carbon dioxide
and pulsed dye laser treatment of angiofibromas in 29
patients with tuberous sclerosis.  Br J Dermatol 2002,
147:337-342.
28. Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW: Use of isogenic
human cancer cells for high-throughput screening and drug
discovery.[comment].  Nature Biotechnology 2001, 19:940-945.
29. Henske EP, Scheithauer BW, Short MP, Wollmann R, Nahmias J,
Hornigold N, van Slegtenhorst M, Welsh CT, Kwiatkowski DJ:
Allelic loss is frequent in tuberous sclerosis kidney lesions
but rare in brain lesions.  Am J Hum Genet 1996, 59:400-406.
30. Henske EP, Wessner LL, Golden J, Scheithauer BW, Vortmeyer AO,
Zhuang Z, Klein-Szanto AJ, Kwiatkowski DJ, Yeung RS: Loss of
tuberin in both subependymal giant cell astrocytomas and
angiomyolipomas supports a two-hit model for the patho-
genesis of tuberous sclerosis tumors.  Am J Pathol 1997,
151:1639-1647.
31. Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, Lewin-Kowalik
J, Kotulska K, Kwiatkowski DJ: Pathogenesis of tuberous sclero-
sis subependymal giant cell astrocytomas: biallelic inactiva-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Dermatology 2008, 8:1 http://www.biomedcentral.com/1471-5945/8/1
Page 9 of 9
(page number not for citation purposes)
tion of TSC1 or TSC2 leads to mTOR activation.  J Neuropathol
Exp Neurol 2004, 63:1236-1242.
32. El-Hashemite N, Zhang H, Henske EP, Kwiatkowski DJ: Mutation in
TSC2 and activation of mammalian target of rapamycin sig-
nalling pathway in renal angiomyolipoma.  Lancet 2003,
361:1348-1349.
33. Au KS, Hebert AA, Roach ES, Northrup H: Complete inactivation
of the TSC2 gene leads to formation of hamartomas.  Am J
Hum Genet 1999, 65:1790-1795.
34. Fackler I, DeClue JE, Rust H, Vu PA, Kutzner H, Rutten A, Kaddu S,
Sander CA, Volkenandt M, Johnson MW, Vinters HV, Wienecke R:
Loss of expression of tuberin and hamartin in tuberous scle-
rosis complex-associated but not in sporadic angiofibromas.
J Cutan Pathol 2003, 30:174-177.
35. Ormerod AD, Shah SA, Copeland P, Omar G, Winfield A: Treat-
ment of psoriasis with topical sirolimus: preclinical develop-
ment and a randomized, double-blind trial.  Br J Dermatol 2005,
152:758-764.
36. Meingassner J, Stutz A: Anti-Inflammatory Effects of Macrophi-
lin-Interacting Drugs in Animal Models of Irritant and Aller-
gic Contact Dermatitis.  Int Arch Allergy Immunol 1992, 99:486-489.
37. Baumer W, Sulzle B, Weigt H, De Vries VC, Hecht M, Tschernig T,
Kietzmann M: Cilomilast, tacrolimus and rapamycin modulate
dendritic cell function in the elicitation phase of allergic con-
tact dermatitis.  Br J Dermatol 2005, 153:136-144.
38. Mathew T, Kreis H, Friend P: Two-year incidence of malignancy
in sirolimus-treated renal transplant recipients: results from
five multicenter studies.  Clin Transplant 2004, 18:446-449.
39. Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM,
Claesson K, Stallone G, Russ G, Rostaing L, Kreis H, Burke JT, Brault
Y, Scarola JA, Neylan JF: Sirolimus therapy after early
cyclosporine withdrawal reduces the risk for cancer in adult
renal transplantation.  J Am Soc Nephrol 2006, 17:581-589.
40. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV: Conversion to
sirolimus: a successful treatment for posttransplantation
Kaposi's sarcoma.  Transplantation 2004, 77:760-762.
41. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G,
Ranieri E, Gesualdo L, Schena FP, Grandaliano G: Sirolimus for
Kaposi's sarcoma in renal-transplant recipients.  N Engl J Med
2005, 352:1317-1323.
42. Koehl GE, Andrassy J, Guba M, Richter S, Kroemer A, Scherer MN,
Steinbauer M, Graeb C, Schlitt HJ, Jauch KW, Geissler EK: Rapamy-
cin protects allografts from rejection while simultaneously
attacking tumors in immunosuppressed mice.  Transplantation
2004, 77:1319-1326.
43. Wienecke R, Klemm E, Karparti S, Swanson NA, Green AJ, DeClue
JE: Reduction of expression of tuberin, the tuberous-sclero-
sis-complex-gene-2 product in tuberous sclerosis complex
associated connective tissue nevi and sporadic squamous
and basal cell carcinomas.  J Cutan Pathol 2002, 29:287-290.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-5945/8/1/prepub